Biopharma set for a big buyout year – on dollar terms at least
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Big cap stocks grow in first half despite M&A activity, not because of it
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Abbvergan by numbers
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
A Botox filler for Abbvie's Humira-shaped hole
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Abbvie proves the best at getting the most out of its workers
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.